Show Me the Data: Enable the Transition from Volume to Value Using Your Electronic Health Record
Roche Diagnostics
Monday June 4, 1400-1500
Patrick C. Mathias, M.D., Ph.D.
General Objectives:
At the conclusion of this session, participants will be able to:
- Describe effective laboratory stewardship strategies.
- Identify data that assists in selecting test ordering improvement opportunities.
- Implement EHR interventions to promote laboratory stewardship.
Did you know that implementing simple laboratory practices such as analyzing different characteristics of laboratory orders to identify potential test ordering improvement opportunities and one or more electronic health record (EHR) interventions can help improve your lab’s stewardship efforts? In this workshop, Patrick C. Mathias, M.D., Ph.D., shows you how using data can help your laboratory enable a transition from volume to value.
Managing the Risk of Patient Harm from Erroneous Results
Bio-Rad Laboratories (Canada) Ltd.
Monday June 4, 1400-1500
Danny Gauvreau, Bio-Rad Laboratories
John Yundt-Pacheco, Bio-Rad Laboratories
General Objectives:
At the conclusion of this session, participants will be able to:
- Understand how a QC strategy relates to the risk of producing erroneous results during an out-of-control condition.
- Understand how test method performance, reliability, and clinical utility affect our tolerance for erroneous results.
- Understand how to determine an acceptable probability of patient harm.
- Understand how to compute a predicted probability of patient harm for a test method.
- Understand how to compute a risk management index, comparing predicted probability of patient harm with acceptable probability of patient harm.
This workshop will provide participants with examples of how to evaluate QC strategies in the presence of out-of-control conditions. Once the basic concepts and metrics are covered, they will be used to derive expressions for predicting the rate of producing erroneous results during in-control and out-of-control conditions. An approach for relating erroneous results and patient harm will be covered as will as how to determine acceptable levels of patient harm for a test method. We will end with a discussion of how to compute a risk management index comparing predicted probability of patient harm with acceptable probability of patient harm.
Integrating Procalcitonin into Clinical Diagnosis and Management of Septic Patients to Provide Measurably Better Healthcare
Abbott Laboratories
Monday June 4, 1400-1500
Eric Howard Gluck, M.D.
General Objectives:
At the conclusion of this session, participants will be able to:
- To understand the mechanisms of sepsis and optimal management of septic and potentially septic patients.
- To appreciate the challenges that physicians face when diagnosing sepsis and the importance of integrated clinical care strategies.
- To highlight the value of Procalcitonin-guided treatment pathways for measurable benefits to patients, clinicians, health systems and payors.
Sepsis is a topic of national interest due to its high mortality rate, the time-sensitive nature of providing the appropriate care and the significant financial burden on healthcare systems. Current methods for the diagnosis of sepsis are often non-specific or slow, delaying treatment and/or increasing the possibility of over-treatment. Patient treatment can be enhanced by the use of procalcitonin (PCT), a protein produced and released in response to a bacterial infection. This workshop will review healthcare implications of sepsis, discuss implementation of PCT into clinical care and highlight the measurable benefits of PCT-guided pathwayians, health systems and payors.
Initial Method Validation of the Randox Multistat System in a Routine Clinical Biochemistry Laboratory
ESBE Scientific
Monday June 4, 1600-1700
Dr. Nathalie Lepage, PhD, FCACB, Hôpital Montfort
Renee-Claude Baril, Hôpital Montfort
Pankaj Sinha, Randox Toxicology
General Objectives:
At the conclusion of this session, participants will be able to:
- Discuss a new multiplexing technology with future application to the clinical toxicology setting.
The session will cover the scientific fundamentals of Randox biochipTM multiplex technology and it’s application for use as a urine toxicology screening tool. Evaluation test results and operational performance of the biochip with Randox’s smallest platform called MultiSTAT will be discussed in detail.
High-Sensitivity Cardiac Troponin – A Test That Offers High-Expectations for Laboratories, Clinicians, and Patients
Beckman Coulter Canada
Monday June 4, 1600-1700
Peter Kavsak, Hamilton Health Sciences
Joe Bottos, Beckman Coulter Canada
General Objectives:
At the conclusion of this session, participants will be able to:
- Current consensus on the definition of high-sensitivity cardiac troponin (hs-cTn) assay, any new criteria.
- Better understand the Impact of hs-cTn on clinical practice: ED, patients outside of ACS diagnosis.
- Better understand pre-analytical and analytical issues lab professions should pay attention to.
High-sensitivity cardiac troponin: what does it mean to your laboratory, your clinicians, and your patients.
How Engineering Design and Biochemistry Come Together to Improve Patient Care; Atellica™ Solution Assays in a New Light
Siemens
Monday June 4, 1600-1700
Frank Vitzhum, Global Assay Development, Siemens Healthineers
General Objectives:
At the conclusion of this session, participants will be able to:
- Learn basic procedural aspects of the development of assay products.
- Understand how certain key features of certain critical components of an assay formulation, in particular acridinium-esters and their conjugates, impact the performance of an assay.
- Learn how engineering features can improve the assay time and the precision of an assay without the need for changing formulations.
The workshop will provide an overview of the development process for assays at Siemens Healthineers. With a focus on immunoassays using the acridinium-ester technology, approaches are discussed on how performance characteristics, in particular assay sensitivity, as well as manufacturability and lot-to-lot consistency can be improved. This will be discussed using examples like the High Sensitivity Troponin I assay. Furthermore, examples from Atellica Solution will be presented to explain benefits of engineering design on time to first result and precision without changing the biochemistry of an assay.
Management of Dysglycemia in Critically Ill Patients – Importance of Glucose Meter Accuracy
Nova Biomedical
Tuesday June 5, 0730-0830
Evan Ntrivalas, MD, PhD, HCLD/CC(ABB), D(ABLMLI), Director of Medical and Scientific Affairs, Nova Biomedical, USA
General Objectives:
At the conclusion of this session, participants will be able to:
- Identify common errors in point of care glucose testing.
- Describe the effect of interferences on POC glucose testing in hospitalized patients.
- Understand the importance of glucose meter accuracy in improving clinical outcomes.
- List the clinical benefits of proper glycemic management in critically ill patients.
Point-of-Care (POC) glucose testing in the hospital is a valuable tool for the management of dysglycemia. This can be undermined by inaccurate POC glucose meter results, which are most often caused by interferences related to patients’ pathophysiologic factors and exogenous substances. The presentation will discuss, using peer-reviewed publications and clinical case studies, the risks posed by interferences in glucose meter results, and how these can potentially affect patient’s safety. Additional factors (such as regulatory issues, user-related errors, and competency assessment) that can have an effect in POC glucose meter performance and potentially influence clinical outcomes will be discussed.
Managing Preanalytic Change in Large Healthcare Systems
BD Canada
Tuesday June 5, 0730-0830
Dr. Anna Fuezery, Alberta Health Services, Calgary AB
Dr. Philippe Mills
General Objectives:
At the conclusion of this session, participants will be able to:
- Describe considerations that go into deciding whether to implement a new blood collection tube for a single versus multiple analytes across a large healthcare system.
- Describe challenges associated with the implementation of a preanalytical change across a large healthcare system.
- Describe change management strategies for the implementation of a preanalytical change across a large healthcare system.
In late 2016 BD Canada released a new blood collection tube called Barricor. The novel, mechanical separation technology of this tube produces a more complete separation of cellular contents from plasma, eliminates gel artifacts, improves sample stability and is only slightly more expensive than BD’s plasma separator tube (PST). Within a span of 6 months in 2017, Alberta Health Services implemented this tube for troponin testing at 13 sites across Edmonton that ranged from a large quaternary care center to a standalone emergency room. In the beginning of 2018, CIUSSS de la Mauricie-et-du-Centre-du-Quebec implemented the tube for all chemistry testing at 9 sites across the region of Trois-Rivieres, with the sites ranging from a tertiary care center to a stand-alone emergency room. This workshop will feature two speakers, each of whom will describe their organization’s approach to the implementation of the tubes. Topics that will be discussed include: 1) reasons behind choosing to implement the Barricor for a single versus multiple analytes; 2) change management pre- and post-implementation, with particular emphasis on the large scale of each implementation; and 3) lessons learned. The workshop will consist of a 5 minute introduction of the speakers, two 25 minute presentations (one presentation per speaker), and a 5 minute question-and-answer period.